Andrew D. Krystal, MD – Program Chair
Associate Professor, Department of Psychiatry
Duke University Medical Center
Durham, NC

Sonia Ancoli-Israel, Ph.D
Professor of Psychiatry
Director, Gillin Sleep and Chronomedicine Research Center
University of California, San Diego
La Jolla, CA

After completing this activity, participants should be able to:

• Describe the basic neuroscience of sleep architecture, and list the most likely causes of dysfunction.
• Differentiate specific MOA of various pharmacologic agents approved and in development to treat specific disruptions in various parts of sleep architecture.
• Recognize a range of common sleep disturbance symptoms presented in clinical practice which may indicate insomnia.
• Identify available assessment tools which may be incorporated into the clinical practice setting to facilitate appropriate screening for diagnosis.
• Illustrate the patient education elements which should be incorporated into the treatment planning process, and recommend appropriate environmental and behavioral activities to mitigate interruptions of sleep.

The activity in its entirety should take approximately 120 minutes to complete.

This activity is supported by an educational grant from

This activity will provide participants with insight into insomnia management through discussions of assessment, treatment implications, and patient education strategies.

This activity is an independent educational activity under the direction of CME LLC. The activity was planned and implemented in accordance with the Essential Areas and policies of the ACCME, the Ethical Opinions/Guidelines of the AMA, the FDA, the OIG, and the PhRMA Code on Interactions with Healthcare Professionals, thus assuring the highest degree of independence, fair balance, scientific rigor, and objectivity.

CME LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CME LLC designates this educational activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The opinions and recommendations expressed by faculty and other experts whose input is included in this activity are their own and do not necessarily reflect the views of the sponsors or supporter. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the faculty or may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Activity participants are encouraged to refer to primary references or full prescribing information resources.

Dr. Krystal is a consultant for and/or has received research support from Abbott, Actelion, Arena, Astellas, Axiom, AstraZeneca, Bristol-Myers Squibb, Cephalon, CHDI, Eli Lilly, Evotec, GlaxoSmithKline, Jazz, Johnson & Johnson, King, Kingsdown, Merck, National Institutes of Health, Neurocrine, Neurogen, Neuronetics, Novartis, Organon, Ortho-McNeil Janssen, Pfizer, Respironics, Research Triangle Institute, Roche, sanofi-aventis, Sepracor, Somaxon, Takeda, and Transcept.

Dr. Ancoli-Isreal is a consultant for Ferring, GlaxoSmithKline, Orphagen, Pfizer, Respironics, sanofi-aventis, Schering-Plough, and Sepracor.

This activity has been independently reviewed for balance.

Participants are required to review the entire presentation and to complete the posttest and evaluation to earn a certificate of completion.

This enduring activity is a spin-off of a live presentation at the 2009 U.S. Psychiatric andMental Health Congress, November 3, 2009, in Las Vegas, NV. If you have earned a certificate for the live session, you are ineligible to earn a certificate for the enduring spin-off.

This continuing medical education activity is intended for psychiatrists, primary care physicians, and other healthcare professionals who seek to improve their care for patients with mental health disorders.